

FOI 3598

19th February 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

How many patients has your Trust treated in the past 12 months (January - December 2025) for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Trust do you refer patients needing treatment to?

Response:

We only track patients until they receive their first definitive treatment. There were 24 new CLL patients treated by SHSCT in 2025.

How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated by the Trust in the past 6 months on the following treatments:

Response:

- BR (bendamustine + rituximab) = 0
- Brukinsa (zanubrutinib) = <5
- Calquence (acalabrutinib) = 37
- Calquence (acalabrutinib) + Gazyva (obinutuzumab) = 0
- Calquence (acalabrutinib) + Venclyxto (venetoclax) = 0
- Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyva (obinutuzumab) = 0
- FCR (fludarabine + cyclophosphamide + rituximab) = 0
- Fludarabine Monotherapy = 0
- Gazyva (obinutuzumab) + chlorambucil = 0
- Imbruvica (ibrutinib) = 11
- Venclyxto (venetoclax) = 13
- Venclyxto (venetoclax) + Gazyva (obinutuzumab) = 0
- Venclyxto (venetoclax) + rituximab = 0
- Zydelig (idelalisib) + rituximab = 0

- Imbruvica (Ibrutinib) +Venclyxto (venetoclax) = <5
- Any other systemic anti-cancer therapy – unable to answer

The Trust has a legal duty to protect patient confidentiality, in line with this duty the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

How many Chronic Lymphocytic Leukaemia (CLL) patients have received treatment for relapsed/refractory CLL in the past 6 months with the following:

Response:

Unable to answer – records do not record if relapsed/refractory.

- Brukinsa (zanubrutinib)
- Calquence (acalabrutinib)
- Imbruvica (ibrutinib)
- Venclyxto (venetoclax)
- Zydelig (idelalisib) + rituximab
- Any other systemic anti-cancer therapy

If your Trust does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If yes, please can you provide details of the ongoing trials.

Response:

There are no current trials open for CLL patients attending the SHSCT.

All patient are discussed at Multi-Disciplinary meetings and consideration is given to any open trials for these patients.

There are currently no active trials for these patients in any of the Trusts.

Email: Foi.Team@Southerntrust.hscni.net